NCT05366361 The Dynamics of Human Atrial Fibrillation
| NCT ID | NCT05366361 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2020-08-18 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2020-08-18 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.
Eligibility Criteria
Inclusion Criteria: * referred for ablation or Maze surgery at Stanford Medicine for persistent AF (i.e. which requires cardioversion to terminate and/or lasts \>7 days) * Per our clinical practice and guidelines (Calkins et al., Heart Rhythm 2018), patients will have failed or be intolerant of \>or= 1 anti-arrhythmic drug. Patients after Maze surgery typically have failed prior endocardial ablation. Exclusion Criteria: * active coronary ischemia or decompensated heart failure * atrial or ventricular clot on trans-esophageal echocardiography * pregnancy (to minimize fluoroscopic exposure) * inability or unwillingness to provide informed consent * rheumatic valve disease (results in a unique AF phenotype) * thrombotic disease or venous filters * prior chest surgery is a relative contraindication for Maze surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05366361 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 80 Years, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05366361 currently recruiting?
Yes, NCT05366361 is actively recruiting participants. Contact the research team at ansonlee@stanford.edu for enrollment information.
Where is the NCT05366361 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT05366361 clinical trial?
NCT05366361 is sponsored by Stanford University. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.